Guidance Documents

This is a revision of previously approved and posted Q&As, that were published on March 31, 2020.  DEA-DC-9.  This  document replaces three of the questions posted within DEA-DC-9 and provides information regarding what EPCS is, remote identity proofing, and if qualified practitioners are allowed to use EPCS to issue prescriptions for CIII-V CS approved by the FDA for MOUD.

The Bureau of Alcohol, Tobacco, Firearms and Explosives (“ATF”) is issuing this open letter to assist Federal Firearms Licensees (“FFLs”) in understanding their obligations when they choose to provide firearm storage services to their customers and the public.

This Practitioner’s Manual has been prepared by the DEA, Diversion Control Division, as a guide to assist practitioners in their understanding of the federal Controlled Substances Act and its implementing regulations as they pertain to their profession.

Disposal of Controlled Substance Prescription Medications (Schedules II-V) Abandoned by Patients and Visitors at DEA-registered Hospital/Clinics, Narcotic Treatment Programs, and Practitioners’ and Mid-Level Practitioners’ Registered Locations.

What’s In This Issue: New Chief, EIPB; Importation and Manufacture of Small Arms Ammunition and Components; Importation of Articles Pyrotechnic Marked as Display Fireworks; Indoor Storage in Residences/Dwellings; Open letter – Electronic Nicotine Delivery Systems; Distance Requirements for Ammonium Nitrate Products; Black Powder Exemption Reminder; Less Lethal Munitions Marking Requirements; ATF Ruling 2011-3 Reminder; and more.

This document informs DEA registrants impacted by the flexibilities DEA granted during the COVID-19 PHE, which flexibilities will automatically terminate at the conclusion of the COVID-19 PHE on May 11, 2023, and which flexibilities will remain in effect after May 11, 2023 under the Opioid Crisis PHE. The document also informs DEA registrants of newly published proposed rules intended to make some exceptions related to the COVID-19 PHE permanent.

This guidance document clarifies the requirement for Drug Enforcement Administration (DEA) registrant-transferors to use multiple single-sheet DEA Form 222s (order forms) when transferring schedule I or II controlled substances to a DEA registrant-transferee when the number of items being transferred exceeds the number of lines available on the order form.

This guidance document provides information regarding a practitioner’s use of existing Drug Enforcement Administration (DEA)-Form 222s after Congress’s elimination of the X-waiver (DATA-Waiver) in the Consolidated Appropriations Act (CAA) of 2023.

This guidance document, will be sent via email to all Drug Enforcement Administration registrants to provide clarification for disposal.

This guidance document provides information regarding issuance of updated Drug Enforcement Administration (DEA) registration certificates to reflect Congress’s elimination of the X-waiver (DATA-Waiver) in the Consolidated Appropriations Act (CAA) of 2023.